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Abstract Implementation of point-of-care tests may facilitate
the health management of infectious diseases by reducing the
timeframe on pathogen identification and host response mea-
surements, allowing for immediate diagnosis and guided clin-
ical intervention. In this feasibility study, a novel totally inte-
grated and fully automated real-time polymerase chain reac-
tion (PCR) platform (Idylla™, Biocartis) was assessed to de-
termine the mRNA expression levels of multiple genes from
1 mL of whole blood. To this purpose, a sample-in result-out
assay, including mRNA extraction and RT-qPCR-based detec-
tion, was ported to the platform. The genes used (matrix
metallopeptidase 9, olfactomedin 4, NB1 glycoprotein and
lipocalin 2) were previously identified as predictive for sever-
ity of disease caused by infection with respiratory syncytial
virus (RSV). The reproducibility and robustness of the proto-
type assay was determined using the blood samples of 21
healthy donors. The data showed that the Idylla™ platform
allows for a fast and user-friendly determination of the relative
expression levels of the four selected mRNA markers.
Introduction
Infectious disease diagnostics changed profoundly over
the past decades due to the rapid evolution in the ap-
plication of molecular biological techniques, such as
RT-qPCR. In this paper, a new approach to infectious
disease diagnosis is explored based on the host gene
expression of four selected mRNA markers predicting
infectious disease severity [1–4]. The analysis of host
gene profiles offers tremendous possibilities for the
identification of markers of disease severity and, even-
tually, to predict the course of disease [5]. Parallel to
the increased interest in host gene expression is the
demand for rapid point-of-care testing.
We here assess the performance of a diagnostic plat-
form (Idylla™, Biocartis) offering fully integrated
nucleic acid isolation and multiplex RT-qPCR-based
quantification. This sample-in result-out platform does
not require specific expertise or molecular biological
skills and allows for a minimum number of handlings
before starting the assay run. With its short turn-around
time and fully contained design, it is perfectly suited for
rapid and safe decentralised diagnostics at emergency
units, clinical departments or, ultimately, the general
practitioner’s office.
The main aim of this study was to develop a prototype
assay on the Idylla™ platform starting from 1 mL of EDTA
whole blood measuring the relative expression levels of four
mRNA markers specific for the severity of respiratory syncy-
tial virus (RSV) infections in whole blood. These markers are:
matrix metallopeptidase 9 (MMP9), olfactomedin 4
(OLFM4), NB1 glycoprotein (CD177) and lipocalin 2
(LCN2). They were all significantly upregulated during dis-
ease and were verified using peripheral blood mononuclear
cell samples collected in a large clinical study [6].
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Materials and methods
Sample collection
Whole blood samples were collected from healthy adults who
were enrolled following informed consent. The cohort
consisted of 21 subjects (52.4 % males), with an average age
of 32.5 (20–44) years. Subjects who used any type of medi-
cation were excluded. The clinical information available to the
study subjects included a description of the risks and benefits
of participation and safe handling and protection of all data.
We communicated to all subjects that there was no obligation
to participate and that declining to participate or leaving the
study had no adverse consequences, and written consent was
obtained.
Whole blood samples were collected in EDTA vacutainer
tubes (BD, USA). The samples were kept at room temperature
and immediately transferred to the laboratory, where they
were processed on the Idylla™ platform in the sequence of
sampling.
Idylla™ platform
Idylla™ is a fully automated sample-in result-out molecular
high-precision diagnostic system consisting of one or more
stackable instruments, a console and a disposable cartridge
prefilled with all the necessary reagents for nucleic acid ex-
traction and amplification and that is able to produce polymer-
ase chain reaction (PCR)-based results from a single sample in
about 2 h or less, depending on the complexity of the test, with
a hands-on time of about 2 min (Fig. 1a). After addition of the
clinical material in the cartridge and loading the cartridge into
an instrument slot, all process steps are carried out
automatically.
mRNA isolation and quantification in Idylla™
One mL of EDTAwhole blood was added into the lysis cham-
ber of a research prototype cartridge prefilled with extraction
reagents. The primers and probes from the respective TaqMan
gene expression assays (Applied Biosystems, USA) were pre-
spotted in each of the PCR wells (see Fig. 1b). After the
addition of 100 μL RT-qPCR buffer to the mixing chamber,
the cartridge was closed and added to a slot of the Idylla™
instrument and the automatic run was started, including the
following steps. Firstly, 100 μL (20 mg.mL−1) proteinase K
(Macherey-Nagel, Germany) was added to the blood sample
and homogenized. Subsequently, 1 mL 3 M guanidinium-
based lysis buffer (pH 7.3) was added to the mixture and, once
again, homogenised by pumping the solution back and forth
in the cartridge. Then, 1 mL 70 % ethanol was added to the
lysate and, after mixing, the whole mixture was pumped over
a silica membrane in the extraction chamber. Subsequently,
the membrane was washed by pumping in 300 μLwash buffer
1 (RB2, Macherey-Nagel, Germany), followed by three times
300 μLwash buffer 2 (RB3,Macherey-Nagel, Germany) over
the membrane. The residual ethanol was removed from the
silica membrane by heating the membrane for 6 min. The
nucleic acids were eluted in about 100 μL 10 mM Tris-HCl
pH 7.3 and transported to the mixing chamber. After mixing
the eluate with the RT-PCR buffer (95.25 μL iTaq universal
probes one-step buffer and 4.75 μL iScript, both from Bio-
Rad, USA), 25-μL aliquots of the mixture were pumped into
the PCRwells each containing a primers and probe mixture of
one of the biomarkers MMP9, OLFM4, CD177, LCN2 and
B2M. The TaqMan gene expression assays (Applied
Biosystems, USA) were validated on RNA specificity before
a selection was made for use in the Idylla™ cartridge. The
a s s a y s MMP 9 ( H s 0 0 2 3 4 5 7 9 _m 1 ) , O L FM 4
(Hs00197437_m1), CD177 (Hs00360669_m1), LCN2
(Hs01008571_m1) and B2M (Hs00187842_m1) were used
at 120 % of the manufacturer’s advised concentration. The
RT-PCR programme consisted of an initial incubation time
of 10 min at 50 °C, followed by 2 min at 95 °C and 51 cycles
of 10 s at 95 °C and 20 s at 60 °C. The Cq values were
determined for each individual RT-qPCR reaction and, subse-
quently, the data were normalised by subtracting the Cq value
of the housekeeping gene B2M, resulting in ΔCq values.
Statistical analysis
To assess the normality of the results, the D’Agostino–Pearson
omnibus normality test was used.
Results
TaqMan gene expression assay validation
The mRNA specificity of the different TaqMan gene expres-
sion assays were assessed to exclude background signals from
residual DNA, since the protocol does not include a DNase
treatment (data not shown). This evaluation led to the selec-
tion of specific primers and probe sets to measure the expres-
sion of the housekeeping gene B2M and the target genes
CD177, LCN2, MMP9 and OLFM4 in our integrated assay
on the Idylla™ platform.
Biological variation
Whole blood of 19 healthy adults was analysed in duplicate
and ΔCq values and standard deviations (SDs) were calculated
(Fig. 2). The ΔCq values for all targets are normally distribut-
ed (p=>0.05), except for OLFM4 (p=<0.01).
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Technical variation
Multiple whole blood samples of two healthy adults,
respectively donor A (n=13) and donor B (n=14), were
analysed (see Fig. 2). For each of the donors, one run
did not generate any values, so these runs were exclud-
ed from further analysis. In three runs of both donors,
OLFM4 was not detected. For these, a Cq value of 51
was used for further analysis. The ΔCq values were
analysed on distribution, besides OLFM4 of donor B
(p=<0.05), with all values having a normal distribution
(p=>0.05).
Discussion
In this feasibility study, we assessed the Idylla™ platform for
host gene expression determination in whole blood. To this
end, a fast all-in-one protocol was developed and optimised on
this platform to isolate mRNA from 1 mL of whole blood,
Fig. 1 a The diagnostic processing sequence for use of the Idylla™
platform; from left to right: EDTA vacutainer tubes are used for blood
collection (1), 1 mL of whole blood is introduced into the lysis chamber
of the disposable cartridge (2), the cartridge is inserted into the instrument
to run the automatic mRNA isolation and quantification procedure (3). b
Schematic representation of the cartridge components, the prefilled
reagents and the processing steps taking place in the cartridge, where
the white arrows indicate the path of mRNA
Fig. 2 Normalised mRNA expression [mean ± standard deviation (SD)] of the measured targets for donor A (A) (n=12), donor B (B) (n=13) and 19
donors (C) [CD177 (n=37), LCN2 (n=38), MMP9 (n=38) and OLFM4 (n=36)]. Below the graphs, the average ΔCq values and SDs are given
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followed by a cartridge-compatible one-step RNA specific
RT-PCR protocol for the four mRNA markers (CD177,
LCN2, MMP9 and OLFM4) and the housekeeping gene
(B2M).
This protocol was validated on whole blood samples from
healthy individuals. Firstly, the biological variability for the
four markers was determined using blood samples from 19
individuals. On average, MMP9 showed the highest expres-
sion levels, with a ΔCq value of 5.83, followed by LCN2 and
CD117, with average values of 8.50 and 12.37, respectively.
With an average ΔCq value of 15.56, OLFM4 showed the
lowest expression, which implicates an almost 50,000-fold
lower expression than B2M in blood of healthy individuals.
This low expression is most likely the reason why OLFM4
was missed in about 5 % of the runs. The SDs for CD117 and
OLFM4 are particularly high (2.16 and 1.68, respectively) as
compared to LCN2 and MMP9 (1.01 and 0.4 respectively).
For CD177, this most probably reflects the natural biological
variation among individuals. In the case of OLFM4, this can
also be attributed to the fact that its expression levels are close
to the detection limit of the system.
Secondly, the technical variability was determined using
multiple expression measurements of two donors (A and B).
For both donors, the SDs obtained for CD177, LCN2 and
MMP9 (between 0.35 and 0.69) were considerably lower than
those obtained for the 19 samples of different individuals. This
indicates that the technical variation is less than the biological
variation among individuals. The opposite was observed for
OLFM4, but this is due to the fact that, for each donor, this
marker was missed three times, resulting in substantially in-
creased SDs, because of these outliers.
In conclusion, the data demonstrate that the Idylla™ plat-
form is a fast and highly convenient system able to measure
simultaneously the relative expression levels of different
mRNA markers directly in 1 mL of EDTA whole blood. In
this study, only four markers have been used, but the
multiplexing capability of Idylla™ has the potential to detect
up to 30 markers simultaneously. The sensitivity of the assay
needs to be further improved in order to also reliably measure
low abundant mRNAs (such as OLFM4). Furthermore, to
demonstrate the real clinical value of the assay, additional
studies are needed using larger cohorts, including blood sam-
ples from diseased individuals.
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